{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T02:46:14Z","timestamp":1747190774717,"version":"3.40.5"},"reference-count":28,"publisher":"Wiley","license":[{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017594","name":"Medical and Health Science and Technology Project of Zhejiang Province","doi-asserted-by":"crossref","award":["2021KY143","Y202043474"],"award-info":[{"award-number":["2021KY143","Y202043474"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100008867","name":"Zhejiang Provincial Department of Education","doi-asserted-by":"crossref","award":["2021KY143","Y202043474"],"award-info":[{"award-number":["2021KY143","Y202043474"]}],"id":[{"id":"10.13039\/501100008867","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Computational and Mathematical Methods in Medicine"],"published-print":{"date-parts":[[2022,1,20]]},"abstract":"<jats:p>Background. Domestic bendamustine has been approved for appearing on the market in China in the past two years. The report on bendamustine plus rituximab (BR) in the treatment of Chinese B-cell-associated indolent non-Hodgkin\u2019s lymphoma (iNHL) has not yet been published. This study probed into clinical efficacy of the BR regimen for B-cell-associated iNHL in China as well as the value of \u03b22-microglobulin (\u03b22-MG) as a prognostic factor. Methods. We retrospectively analyzed clinical data of 73 B-cell-associated iNHL patients who received BR treatment in The First Affiliated Hospital, College of Medicine, Zhejiang University from January 2020 to January 2021, including clinical characteristics, therapies, therapeutic efficacy, and prognosis-related factors. Thirty-three patients (45.2%) did not receive any other treatment before the BR regimen, and other patients received CHOP, R-CHOP, and other regimens in the past. The cutoff date for follow-up was May 2021. Clinical characteristics of patients were analyzed. The clinical efficacy of the BR regimen was evaluated. Differences of \u03b22-MG expression before and after treatment were analyzed between the CR+PR group and the SD+PD group. Main outcomes were progression-free survival (PFS) and overall survival (OS). A multivariate Cox regression model was taken to analyze prognostic factors relative to survival rate of patients, and adverse events (AEs) during treatment. Results. The objective response rate (ORR) of B-cell-associated iNHL patients who received BR regimen as first-\/multiline treatment was 79.5%, with complete response (CR) of 37.0%, partial response (PR) of 42.5%, median PFS of 12.1 months (95% confidence interval (CI): 10.9-13.2), and median OS of 15.5 months (95% CI: 14.8-16.1). Before treatment, there was no statistical significance in the \u03b22-MG level between the CR+PR group and the SD+PD group (<jats:inline-formula>\n                     <a:math xmlns:a=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M1\">\n                        <a:mi>p<\/a:mi>\n                        <a:mo>&gt;<\/a:mo>\n                        <a:mn>0.05<\/a:mn>\n                     <\/a:math>\n                  <\/jats:inline-formula>). After treatment, the \u03b22-MG level in the CR group was noticeably lower than that in the SD+PD group (<jats:inline-formula>\n                     <c:math xmlns:c=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M2\">\n                        <c:mi>p<\/c:mi>\n                        <c:mo>&lt;<\/c:mo>\n                        <c:mn>0.05<\/c:mn>\n                     <\/c:math>\n                  <\/jats:inline-formula>). The \u03b22-MG level in the CR+PR group decreased conspicuously after treatment (<jats:inline-formula>\n                     <e:math xmlns:e=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M3\">\n                        <e:mi>p<\/e:mi>\n                        <e:mo>&lt;<\/e:mo>\n                        <e:mn>0.05<\/e:mn>\n                     <\/e:math>\n                  <\/jats:inline-formula>). The \u03b22-MG level in the SD+PD group after treatment was not notably different from that before treatment (<jats:inline-formula>\n                     <g:math xmlns:g=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M4\">\n                        <g:mi>p<\/g:mi>\n                        <g:mo>&gt;<\/g:mo>\n                        <g:mn>0.05<\/g:mn>\n                     <\/g:math>\n                  <\/jats:inline-formula>). According to the median expression level of \u03b22-MG before treatment, patients were divided into two groups. The average PFS of the low expression group was <jats:inline-formula>\n                     <i:math xmlns:i=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M5\">\n                        <i:mn>12.69<\/i:mn>\n                        <i:mo>\u00b1<\/i:mo>\n                        <i:mn>0.77<\/i:mn>\n                     <\/i:math>\n                  <\/jats:inline-formula> months, which was longer than the high expression group (<jats:inline-formula>\n                     <k:math xmlns:k=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M6\">\n                        <k:mn>10.13<\/k:mn>\n                        <k:mo>\u00b1<\/k:mo>\n                        <k:mn>0.74<\/k:mn>\n                     <\/k:math>\n                  <\/jats:inline-formula> months), but the difference between the groups was not statistically significant (<jats:inline-formula>\n                     <m:math xmlns:m=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M7\">\n                        <m:mi>p<\/m:mi>\n                        <m:mo>&gt;<\/m:mo>\n                        <m:mn>0.05<\/m:mn>\n                     <\/m:math>\n                  <\/jats:inline-formula>). Multivariate Cox regression analysis showed that B-cell-associated iNHL subtype was the independent prognostic marker most likely to affect PFS of patients (<jats:inline-formula>\n                     <o:math xmlns:o=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M8\">\n                        <o:mi>p<\/o:mi>\n                        <o:mo>=<\/o:mo>\n                        <o:mn>0.051<\/o:mn>\n                     <\/o:math>\n                  <\/jats:inline-formula>). Incidence of any grade of AEs in all patients was 32.9% (24\/73). Conclusion. B-cell-associated iNHL patients who received BR regimen had favorable clinical efficacy and were tolerable to AEs. Though the \u03b22-MG level in this study could not be used to predict clinical outcome, a lower level before treatment seemed to be implicated in better survival outcomes of patients. Our research also unraveled that B-cell-associated iNHL subtype may be a key factor to patient\u2019s prognosis. Overall, this study offers some important insights into clinical application of the BR regimen for Chinese B-cell-associated iNHL patients.<\/jats:p>","DOI":"10.1155\/2022\/1080879","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T18:05:38Z","timestamp":1642701938000},"page":"1-8","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Efficacy of Bendamustine Plus Rituximab (BR) for B-cell Relevant Indolent Non-Hodgkin\u2019s Lymphoma and Role of \u03b22-MG in Predicting the Efficacy of BR Regimen: A Real-World Retrospective Study in China"],"prefix":"10.1155","volume":"2022","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0290-820X","authenticated-orcid":true,"given":"Yujie","family":"Zhang","sequence":"first","affiliation":[{"name":"Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou City, Zhejiang Province, 310003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9268-8732","authenticated-orcid":true,"given":"Donghua","family":"He","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou City, Zhejiang Province, 310003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1138-089X","authenticated-orcid":true,"given":"Jingsong","family":"He","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou City, Zhejiang Province, 310003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3620-5038","authenticated-orcid":true,"given":"Weijia","family":"Huang","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou City, Zhejiang Province, 310003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-3913","authenticated-orcid":true,"given":"Yang","family":"Yang","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou City, Zhejiang Province, 310003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3809-7894","authenticated-orcid":true,"given":"Zhen","family":"Cai","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou City, Zhejiang Province, 310003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4593-8353","authenticated-orcid":true,"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou City, Zhejiang Province, 310003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.2996"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2017.08.002"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24984"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-692442"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25707"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.11406\/rinketsu.61.598"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2016.1233174"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.8389"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.0001"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.1570"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00605"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03355"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-014-2445-5"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2312"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V46.2.219.219"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810701)48:1<198::aid-cncr2820480131>3.0.co;2-v"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.2165\/11205860-000000000-00000"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001463"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04171-7"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0037"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00848"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1594212"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3470"}],"container-title":["Computational and Mathematical Methods in Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/cmmm\/2022\/1080879.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/cmmm\/2022\/1080879.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/cmmm\/2022\/1080879.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T18:05:46Z","timestamp":1642701946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/cmmm\/2022\/1080879\/"}},"subtitle":[],"editor":[{"given":"Tao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,1,20]]},"references-count":28,"alternative-id":["1080879","1080879"],"URL":"https:\/\/doi.org\/10.1155\/2022\/1080879","relation":{},"ISSN":["1748-6718","1748-670X"],"issn-type":[{"type":"electronic","value":"1748-6718"},{"type":"print","value":"1748-670X"}],"subject":[],"published":{"date-parts":[[2022,1,20]]}}}